– USA, NJ – Matinas BioPharma Holdings, Inc. (NYSE AMERICAN: MTNB) today announced the nomination of Kathryn Penkus Corzo for election to its Board of Directors at its 2021 AGM, scheduled for November 1, 2021.
Matinas BioPharma is a clinical-stage biopharmaceutical company focused on improving the intracellular delivery of critical therapeutics through its paradigm-changing lipid nanocrystal platform delivery technology.
“We are thrilled to nominate Kathryn to our Board of Directors,” said Board Chairman, Herbert Conrad. “Kathryn is a highly-regarded biotechnology executive with an extensive record of drug development accomplishments. Her leadership roles and development successes with major pharmaceutical companies will be extremely valuable to our Company as we develop and expand the utilization of our LNC platform delivery technology.”
The Company also announced that Patrick LePore will not stand for re-election to the Board of Directors at the next AGM.
About Kathryn Penkus Corzo
Ms. Corzo is currently a partner at Takeda Ventures, Inc. and previously Head of Oncology Cell Therapy Development at Takeda Pharmaceuticals, a global, values-based, R&D-driven biopharmaceutical leader headquartered in Japan. Ms. Corzo is located at Takeda’s R&D hub in Cambridge, Massachusetts.
Ms. Corzo said, “I am honored to have been nominated to join the Matinas Board of Directors at such an exciting time for the Company. The LNC platform presents a unique and promising opportunity to transform the intracellular delivery of complex molecules and I look forward to working with the Board and the management team to optimize the value and impact of this potentially disruptive technology.”
About Kathryn Penkus Corzo
Kathryn Corzo is a biotechnology executive who has served in senior leadership roles for several leading biotechnology and pharmaceutical companies. Since February 2020, she has been the Head, Oncology Cell Therapy Development at Takeda Pharmaceuticals responsible for leading and overseeing development of Takeda’s Oncology cell therapy pipeline including collaborations with academic and biotech innovation partnerships. Kathryn recently joined Takeda Ventures as a partner. Previously, Kathryn served in various leadership roles at Sanofi Genzyme (2010-2019) where she was Vice President of R&D and Global Program Head for Myeloma from June 2015 through December 2019. She is credited for steering multi-disciplinary teams advancing therapeutic candidates from early proof of concept through pivotal trials, worldwide regulatory approvals, indication expansions and product launches. She also led an initiative to establish Sanofi’s U.S. R&D innovation center and digital accelerator based in Cambridge, MA. Before Sanofi, she successfully built a two-decade career at Hoffmann-La Roche, Roche Molecular Systems, Eli Lilly and Syndax taking on responsibility in R&D operations, global clinical development, medical affairs, business development, market access and brand management across multiple platforms and indications. Kathryn has worked to improve outcomes for cancer patients and played an integral role in the development of 12 innovative investigational drugs and five therapeutic products.
Kathryn holds an M.B.A. from Massachusetts Institute of Technology Sloan School of Management and a B.S. in Pharmacy from Massachusetts College of Pharmacy.
About Matinas BioPharma
Matinas BioPharma is a biopharmaceutical company focused on improving the intracellular delivery of critical therapeutics through its paradigm-changing lipid nanocrystal delivery platform. The Company is developing its own internal portfolio of products as well as partnering with leading pharmaceutical companies to develop new formulations that take full advantage of the unique characteristics of the LNC platform.
Preclinical and clinical data have demonstrated that this novel technology can provide solutions to many of the complex challenges in achieving safe and effective intracellular delivery, for both small molecules and larger, more complex molecules, such as mRNA, DNA plasmids, antisense oligonucleotides and vaccines. The combination of a unique mechanism of action and flexibility in both the formulation and route of administration (including oral), position Matinas’ LNC technology to potentially become the preferred next-generation intracellular drug delivery vehicle and an important improvement over both lipid nanoparticles and viral vectors.
For more information : https://www.matinasbiopharma.com/
- Disclaimer - News, data, and statements included in this release are intended exclusively for general information purposes. Talent4Boards does not guarantee that news is accurate or about the correct person and accepts neither liability for the consequences of the reader’s reliance, nor responsibility for the accuracy of the information. Nothing in this release should be considered for decisions about referred securities. Products and brand names may be trademarks or registered trademarks of their respective owners.